<DOC>
	<DOCNO>NCT00273390</DOCNO>
	<brief_summary>This project design test hypothesis inhibition bind tumor necrosis factor alpha ( TNF-alpha ) receptor use Remicade ( infliximab , chimeric mouse/human IgG1K monoclonal antibody direct human TNF-alpha , Centocor , Malvern , PA ) clinically useful patient uveitis refractory form systemic immunosuppressive therapy .</brief_summary>
	<brief_title>A Clinical Trial Infliximab Uveitis</brief_title>
	<detailed_description />
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>1 . The study group include patient suffer treatmentresistant visionthreatening uveitis attend Uveitis Clinic Casey Eye Institute . 2 . We plan enroll 32 patient . 1 . Patients ocular systemic infection . 2 . Patients subtype uveitis term par planitis MRI scan evidence demyelination . There theoretical risk adverse outcome TNFalpha inhibition clinical course multiple sclerosis . Patients suffer pars planitis increase risk develop multiple sclerosis . 3 . Children age 9 . 4 . Patients know sensitivity mouse protein . Remicade chimeric protein human murine component . 5 . Patients history cancer ( exception skin cancer curatively resect ) , organ transplantation ( exception cornea ) , recent drug alcohol addiction , inability keep appointment . 6 . Patients serious systemic disease could interfere participation study . 7 . It specifically note pregnant woman nurse mother exclude study .</criteria>
	<gender>All</gender>
	<minimum_age>9 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
</DOC>